Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

Sanofi SA

FranceAdoptersAssignment FullData quality Medium

Key messagelimited AI Footprint

Sanofi uses artificial intelligence widely in research, trials, drug safety and production and has principles, an internal review procedure for high-risk applications and a cybersecurity organisation described in its annual report. Who currently oversees these rules at board or executive committee level, and how well individual systems are tested, the company does not disclose.

Disclosure: the research was supported by an AI model made by Anthropic. Sanofi SA is connected to Anthropic (e.g. as investor, partner, supplier, customer or through people). The assessment was therefore reviewed by people.

Opportunities

  • Safetysolid

    The cybersecurity disclosure in the 2025 20-F documents a specific structure: NIST framework, penetration testing and attack simulations, a security operations centre, supplier assessments, an escalation plan and oversight by the Risk Committee and Audit Committee, with a CISO in office since 2014 (S02, S03).

    The cybersecurity disclosure in the 2025 20-F documents a specific structure: NIST framework, penetration testing and attack simulations, a security operations centre, supplier assessments, an escalation plan and oversight by the Risk Committee and Audit Committee, with a CISO in office since 2014 (S02, S03). For AI itself there are only company statements on controls (human review, performance monitoring and drift control for Turing and risk models, human oversight for ARTEMIS and regulatory texts) without independent review (S08, S09, S30, S32). No AI or data controversy is documented in the period; the 2025 hacker claim is unconfirmed (S34, S04).

Risks

  • Responsibilitylimited

    Sanofi itself describes a review and risk classification procedure for AI: a Responsible AI Working Committee (04/2023), an interim body to review high-risk applications (10/2023, around 20 cases), an internal AI policy (12/2023) and a standardised AI Risk Assessment (02/2024, around 50 systems) …

    Sanofi itself describes a review and risk classification procedure for AI: a Responsible AI Working Committee (04/2023), an interim body to review high-risk applications (10/2023, around 20 cases), an internal AI policy (12/2023) and a standardised AI Risk Assessment (02/2024, around 50 systems) (S08, S06, S10); the 2025 20-F confirms a group-wide governance body for AI initiatives and a GenAI charter (S01). However, AI-specific oversight by the board, a board committee or the executive committee that explicitly names AI is not documented: the board charter assigns AI to no committee (S05, S24), the composition and mandate of the AI body are not disclosed, and the Chief Digital Officer is no longer listed on the current executive committee list (S23). The pillar therefore remains “limited” at the level of principles; in addition, there are no recent metrics, no external audit and no AI-specific complaint channel (S13).

  • Transparencylimited

    Sanofi discloses its AI applications widely and commits to communicating when and how AI is used and where its limits lie (S06, S07); however, model cards and explainability methods are described only as internal practice and are not published (S09).

    Sanofi discloses its AI applications widely and commits to communicating when and how AI is used and where its limits lie (S06, S07); however, model cards and explainability methods are described only as internal practice and are not published (S09). Only CodonBERT is publicly traceable with code, training data IDs and a preprint (S33), which covers only a research model with low harm potential. A transparency report, public system cards or information on labelling towards trial participants, healthcare professionals or patients are missing.

  • Risk area

    AI in drug safety and clinical trials

  • Risk area

    AI in regulatory and quality documents and in portfolio decisions

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
41searches
37pages and documents read
10primary documents
1controversies checked
6open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
Sanofi SAOverall rating: limited

Sanofi documents a group-wide AI governance body, a review procedure for high-risk AI and a specific cybersecurity organisation. A board committee responsible for AI is missing, and model cards remain internal.

Responsibility

40 %
limitedsolidstrong

A review procedure and a policy are documented, but AI oversight at the top is not.

  • +20-F confirms an AI governance body and a GenAI charter Source ↗
  • +AI Risk Assessment with around 50 systems and 20 high-risk reviews Source ↗
  • +External compliance helpline with published figures Source ↗
  • –No board committee responsible for AI Source ↗
  • –No Chief Digital Officer on the executive committee list any more Source ↗
All sources for this pillar (13)

Transparency

20 %
limitedsolidstrong

AI applications are widely disclosed, but model cards remain internal.

  • +Detailed public list of AI applications Source ↗
  • +CodonBERT public with code, weights and training data IDs Source ↗
  • –Model cards only as internal practice Source ↗
  • –No labelling towards trial participants or patients documented
  • –No transparency report
All sources for this pillar (6)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
AI oversight on the board

Assign AI to a board committee and, after the change of leadership, clearly to an executive committee member, and publish current figures.

2Safety
Document AI validation

Publish validation and test results for AI in drug safety and trials and have them independently reviewed.

3Transparency
Publish system cards

Publish system cards for ARTEMIS, Muse and Concierge covering purpose, limits and data provenance.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← Sanofi SA is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
1 1 minor

No deduction for controversies.

Largest risk area
AI errors affecting patient safety

Sanofi uses AI to automate the capture of more than 700,000 adverse event reports a year and uses risk models for trial participants without publishing validation results.

How thoroughly assessed
29 Evidence

10 primary documents read, 41 searches.

Read the full reasoning and all sources
Sanofi SA · Full reasoning

AI body and review procedure documented, but no AI oversight on the board

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

The 20-F confirms a group-wide AI body and a GenAI charter, and Sanofi documents a risk procedure with around 50 assessed systems; however, the process information dates from 2024, and since the change of CEO no Chief Digital Officer is listed on the executive committee.

What is documented
  • The 2025 20-F confirms a group-wide governance body for AI initiatives and a GenAI charter for employees1
  • Sanofi documents a Responsible AI Working Committee since April 2023, a body for high-risk applications and an internal AI policy in the employee and supplier codes4 13
  • The AI Risk Assessment classifies applications by purpose, data, model and use; by May 2024 around 50 systems had been submitted and around 20 high-risk cases reviewed4
  • The principles require risk-based controls also for third-party AI and training of all employees in responsible AI9
  • The externally operated compliance helpline recorded 1,095 reports and 333 substantiated cases in 202511
The case against
Oversight at the top unclear
  • The board charter assigns AI, digital and data to no committee; the Audit Committee has only general risk oversight3 8
  • Since the 2026 change of CEO, no Chief Digital Officer is listed on the current executive committee list7 2
Evidence older and unverified
  • The process information comes from a company account of May 2024; more recent figures are missing4
  • No external audit or certification of AI management and no AI-specific complaint channel were found12
Sources for Responsibility (13)
  1. Sanofi: Annual Report on Form 20-F 2025 (fiscal year ended 2025-12-31) · 17 February 2026 · primary source
  2. Sanofi (SEC EDGAR, XBRL): Form 20-F FY2025, R53: Cybersecurity Risk Management and Strategy Disclosure · 17 February 2026 · primary source
  3. Sanofi (SEC EDGAR): Exhibit 1.2 to Form 20-F 2025: Board Charter (internal rules), approved by the board on 2025-04-30 · 17 February 2026 · primary source
  4. Sanofi (Magazin): All in on AI, Accountable to Outcomes · 16 May 2024 · primary source
  5. Sanofi: Principles on Data Ethics (September 2024, approved by the Bioethics Committee) · 1 September 2024 · secondary source
  6. Sanofi: Sanofi Bioethics Framework · 3 November 2026 · secondary source
  7. Sanofi: Executive Committee (web page, as retrieved) · 3 November 2026 · secondary source
  8. Sanofi: Governance (web page) · 3 November 2026 · secondary source
  9. Sanofi: Responsible AI Guiding Principles · 3 November 2026 · secondary source
  10. LeMondeInformatique: Sanofi accélère sur sa stratégie GenAI · 18 June 2025 · secondary source
  11. Sanofi: ESG Index: Ethics and Business Integrity · 31 December 2025 · primary source
  12. Sanofi: Sustainability Statement 2025 (chapter 3 of the URD 2025) · 17 February 2026 · primary source
  13. LeMondeInformatique: Sanofi travaille sur une IA plus éthique · 3 June 2024 · secondary source

2 · Safety

solidWeight 40%

The 20-F documents a cybersecurity organisation based on NIST with penetration testing, a security operations centre and committee oversight; for AI itself there are only company statements on human review and monitoring.

What is documented
  • Item 16K describes prevention, detection, response and recovery based on NIST, penetration testing, attack simulations, a security operations centre and supplier assessments6 7
  • The Risk Committee and Audit Committee oversee cybersecurity; the CISO has been in office since 20146 7
  • For Turing no action is taken without human review; risk models for trial participants have model cards and drift monitoring1 2
  • According to Sanofi, ARTEMIS for adverse event reports and generative AI in regulatory documents run under human oversight4 5
  • The 20-F names no material cyber incident; a 2025 hacker claim is unconfirmed7 10
The case against
AI testing only self-reported
  • The controls for AI rest on company statements without independent review1 4
  • Validation methodology, accuracy figures and red teaming of generative systems are not published
Further gaps
  • Certifications such as ISO/IEC 27001 and specific protection of the AI platforms are not documented
  • No statement by Sanofi on the 2025 claim by the R00TK1T group was found10
Sources for Safety (10)
  1. Sanofi (Magazin): All in on AI, Accountable to Outcomes · 16 May 2024 · primary source
  2. Sanofi (Magazine): AI: Transparent and Explainable · 3 November 2026 · secondary source
  3. LeMondeInformatique: Sanofi accélère sur sa stratégie GenAI · 18 June 2025 · secondary source
  4. Campus Sanofi (Spain): IA en farmacovigilancia: Sanofi automatiza el análisis de efectos adversos en tiempo real (ARTEMIS) · 2 October 2025 · secondary source
  5. DGRA / Sanofi (Yves Jacob, Head Regulatory Europe): Presentation at the DGRA annual congress 2025 · 8 May 2025 · secondary source
  6. Sanofi (SEC EDGAR, XBRL): Form 20-F FY2025, R53: Cybersecurity Risk Management and Strategy Disclosure · 17 February 2026 · primary source
  7. Sanofi (SEC EDGAR, XBRL): Form 20-F FY2025, R55: Cybersecurity Risk Management and Strategy Disclosure (Tagging) · 17 February 2026 · primary source
  8. Sanofi: Sécurité de l'information et confidentialité des données (ESG Index) · 3 November 2026 · secondary source
  9. Sanofi (SEC EDGAR, XBRL): Form 20-F FY2025, R36: Legal and arbitral proceedings (Note D.22) · 17 February 2026 · primary source
  10. The Cyber Express: R00TK1T Announces Cyberattack on Sanofi, Raises Alarming Human Experimentation Claims (Tag-Seite) · 9 July 2025 · secondary source

3 · Transparency

limitedWeight 20%

Sanofi describes its AI applications publicly and commits to communicating their use and limits, but publishes code and model information only for the research model CodonBERT.

What is documented
  • Sanofi publicly describes its AI applications in research, trials, manufacturing and sales3
  • The principles commit to communicating when and how AI is used and where its limits lie, and to enabling users to reject results2
  • Explainable models and feature contributions are used for risk models, and explainability statistics for Turing4 5
  • CodonBERT is public with code, weights, training data IDs and licences6
The case against
Documentation remains internal
  • Model cards and explainability methods are described only as internal practice and are not published5
  • There are no public system cards and no transparency report for ARTEMIS, Muse and Concierge
  • Labelling towards trial participants, healthcare professionals or patients is not documented
Sources for Transparency (6)
  1. Sanofi: Annual Report on Form 20-F 2025 (fiscal year ended 2025-12-31) · 17 February 2026 · primary source
  2. Sanofi: Responsible AI Guiding Principles · 3 November 2026 · secondary source
  3. Sanofi: Artificial Intelligence across Sanofi · 3 November 2026 · secondary source
  4. Sanofi (Magazin): All in on AI, Accountable to Outcomes · 16 May 2024 · primary source
  5. Sanofi (Magazine): AI: Transparent and Explainable · 3 November 2026 · secondary source
  6. Sanofi-Public (GitHub): CodonBERT README · 3 November 2026 · primary source

4 · Why the harm rule does not apply

The harm rule does not apply: within the window there is no judgment, authority decision or fine on harm from AI. The only recorded controversy is an unconfirmed 2025 hacker claim with no documented link to AI.

5 · Controversies (1)

6 · What remains open

  • Governance, board and risk chapters of the 2025 20-F and URD, which were truncated on retrieval
  • Responsibility for AI and digital after the 2026 change of leadership
  • Current figures on AI risk reviews and training after 2024
  • Validation and test results for AI in drug safety and trials
  • Approval procedure for models purchased from external providers
  • Chapters on data protection and governance in the 2025 sustainability statement

7 · How it was assessed

Cut-off date: 3 November 2026 · 41 searches, 37 fetches.

Primary documents read (10)
  • Form 20-F FY2025 (Item 3.D Risk Factors pp. 1–14) and XBRL R36, R53, R55
  • Exhibit 1.2 Board Charter (2025-04-30)
  • Document d'enregistrement universel 2025 (up to p. 14)
  • Sustainability Statement 2025 (pp. 1–27)
  • Minutes of the Annual General Meetings 2025 and 2026
  • Responsible AI Guiding Principles
  • Principles on Data Ethics (September 2024)
  • Sanofi Bioethics Framework
  • ESG Index pages: Ethics and Business Integrity and Sécurité de l'information et confidentialité des données
  • Press releases dated 12 February 2026 and 17 February 2026

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next